

Isolation and Characterization of Klebsiella Phages for Phage Therapy

Townsend, Eleanor M; Kelly, Lucy; Gannon, Lucy; Muscatt, George; Dunstan, Rhys; Michniewski, Slawomir; Sapkota, Hari; Kiljunen, Saija J; Kolsi, Anna; Skurnik, Mikael; Lithgow, Trevor; Millard, Andrew D; Jameson, Eleanor

PHAGE (New Rochelle, N.Y.)

DOI:

[10.1089/phage.2020.0046](https://doi.org/10.1089/phage.2020.0046)

Published: 17/03/2021

Publisher's PDF, also known as Version of record

[Cyswllt i'r cyhoeddiad / Link to publication](#)

Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):

Townsend, E. M., Kelly, L., Gannon, L., Muscatt, G., Dunstan, R., Michniewski, S., Sapkota, H., Kiljunen, S. J., Kolsi, A., Skurnik, M., Lithgow, T., Millard, A. D., & Jameson, E. (2021). Isolation and Characterization of Klebsiella Phages for Phage Therapy. *PHAGE (New Rochelle, N.Y.)*, 2(1), 26-42. <https://doi.org/10.1089/phage.2020.0046>

Hawliau Cyffredinol / General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Isolation and Characterization of *Klebsiella* Phages for Phage Therapy

Eleanor M. Townsend, PhD,¹ Lucy Kelly, MSc,¹ Lucy Gannon, BSc,² George Muscatt, MSc,¹ Rhys Dunstan, PhD,³ Slawomir Michniewski, PhD,¹ Hari Sapkota, MSc,⁴ Saija J. Kiljunen, PhD,^{5,6} Anna Kolsi, BSc,⁵ Mikael Skurnik, PhD,^{5,6} Trevor Lithgow, PhD,³ Andrew D. Millard, PhD,² and Eleanor Jameson, PhD¹

Abstract

Introduction: *Klebsiella* is a clinically important pathogen causing a variety of antimicrobial resistant infections in both community and nosocomial settings, particularly pneumonia, urinary tract infection, and sepsis. Bacteriophage (phage) therapy is being considered a primary option for the treatment of drug-resistant infections of these types.

Methods: We report the successful isolation and characterization of 30 novel, genetically diverse *Klebsiella* phages.

Results: The isolated phages span six different phage families and nine genera, representing both lysogenic and lytic lifestyles. Individual *Klebsiella* phage isolates infected up to 11 of the 18 *Klebsiella* capsule types tested, and all 18 capsule-types were infected by at least one of the phages.

Conclusions: Of the *Klebsiella*-infecting phages presented in this study, the lytic phages are most suitable for phage therapy, based on their broad host range, high virulence, short lysis period and given that they encode no known toxin or antimicrobial resistance genes. Phage isolates belonging to the *Sugarlandvirus* and *Slopekvirus* genera were deemed most suitable for phage therapy based on our characterization. Importantly, when applied alone, none of the characterized phages were able to suppress the growth of *Klebsiella* for more than 12 h, likely due to the inherent ease of *Klebsiella* to generate spontaneous phage-resistant mutants. This indicates that for successful phage therapy, a cocktail of multiple phages would be necessary to treat *Klebsiella* infections.

Keywords: *Klebsiella*, bacteriophage, phage, phage therapy, antimicrobial resistance, antibiotics, nosocomial infection, characterization, virulence

Background

THE *KLEBSIELLA* GENUS causes pneumonia, urinary tract infection, and sepsis, particularly in vulnerable populations, often causing secondary infections in ventilated or catheterized patients, in both the community and nosocomial settings.^{1–4} In addition, the subclinical carriage of *Klebsiella* is linked to cardiovascular^{5,6} and inflammatory bowel disease.⁷ *Klebsiella pneumoniae* is the most problematic species giving rise to hypervirulent clones with extended virulence factors.^{8–11}

Antimicrobial resistance (AMR) represents a threat to global health and security, fueled by our intensive use of

antibiotics in medicine and agriculture. *Klebsiella* readily gains and transfers AMR genes, particularly in health care settings, making it a World Health Organization priority pathogen.^{12,13} The prevalence of multi-drug resistant (MDR) *Klebsiella* has increased exponentially to most available antimicrobial drugs, and cases of pan-resistant *Klebsiella* are now common around the world.^{14–17} MDR *Klebsiella* infections pose an increased risk of mortality,^{18,19} are difficult to treat^{20,21} and outbreaks are economically costly.¹⁹ Bacteriophages (phages)²² offer one potential alternative treatment.

Phage therapy is a potential weapon against MDR bacterial infections.^{23,24} Phage therapy depends on preparedness,

¹Department of Microbiology and Virology, School of Life Sciences, Gibbet Hill Campus, The University of Warwick, Coventry, United Kingdom.

²Department of Genetics, University of Leicester, Leicester, United Kingdom.

³Infection and Immunity Program, Department of Microbiology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia.

⁴Department of Neuroscience, Psychology and Behaviour, University of Leicester, Leicester, United Kingdom.

⁵Department of Bacteriology and Immunology, Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

⁶Division of Clinical Microbiology, Helsinki University Hospital, HUSLAB, Helsinki, Finland.

particularly in having a real or virtual “biobank” of characterized phages against common AMR bacteria. Phage characterization is essential to provide effective, timely treatment and mitigate side effects.²⁵

In this article, we use genomic and imaging technologies to characterize novel phages isolated against *Klebsiella* spp. Phages were isolated from rivers, ponds, estuaries, canals, slurry, and sewage. Their characterization focused on their infection cycle, host range, and gene content. We present phages with siphovirus, myovirus, podovirus, and inovirus morphologies, spanning six phage families and nine genera, of which the majority have lytic lifestyles. A number of these phages have potential use in phage therapy.

Materials and Methods

Bacterial strains and culture conditions

The *Klebsiella* strains used in this work are listed in Table 1. All culturing in liquid medium was performed with shaking (150 rpm) at 37°C. All culturing was carried out in Lysogeny broth (LB), with the addition of 5 mM CaCl₂ and MgCl₂. The *Klebsiella* were originally isolated from clinical and environmental samples (Table 1). They represented six species: *K. pneumoniae*, *Klebsiella oxytoca*, *Klebsiella quasipneumoniae*, *Klebsiella variicola*, *Klebsiella michiganensis*, and *Klebsiella aerogenes*.

No ethical approval was required for this work.

Klebsiella capsule typing

Kaptive Web was used to determine the capsule (K) and LPS antigen (O) locus types of the 24 *Klebsiella* strains.

Phage isolation

Phages were isolated from water samples from various sources, listed in Table 2. Water samples were filtered through 0.2 μm pore-size syringe filters to remove debris and bacteria. Phages were then isolated by enrichment: 2.5 mL of filtered water was added to 2.5 mL nutrient broth, containing 5 mM CaCl₂ and 5 mM MgCl₂, and inoculated with 50 μL of overnight-grown *Klebsiella*. This enrichment culture was then incubated overnight at 37°C and centrifuged, and the supernatant was filtered through a 0.2 μm pore-size filter to remove cells. This filtrate was serially diluted to 10⁻¹¹ in LB and used in an overlay agar plaque assay.

Briefly, 50 μL of each serial dilution was mixed with 0.5 mL of a single *Klebsiella* strain in the logarithmic growth phase (approximately OD_{600nm} 0.2) and incubated at room temperature for 5 min. To each serial dilution/cell mix, 2.5 mL of cooled, molten LB agar (0.4% weight/volume) was added and mixed by swirling. The molten agar mix was poured onto 1% LB agar plates. Overlay agar plates were allowed to set, then inverted, and incubated overnight at 37°C. From the plaque assay plates, single plaques were picked, mixed with 50 μL of LB, and filtered through a 0.22 μm pore-size spin filter (Costar Spin-X; Corning, United Kingdom). This filtrate underwent two further rounds of plaque assay to ensure that clonal phages were isolated. Phages were named by using the ICTV binomial system of viral nomenclature.²⁶

DNA extraction

DNA was extracted by using the phenol–chloroform method.²⁷ Briefly, phage lysates were concentrated by using

TABLE 1. DETAILS OF *KLEBSIELLA* SPECIES AND STRAINS USED IN THIS STUDY

Species	Strain	Capsule (K) and LPS antigen (O) locus	Isolation host?	Origin	Isolation source
<i>Klebsiella aerogenes</i>	30053	—	✓	DSMZ Culture Collection	Sputum
<i>Klebsiella michiganensis</i>	25444	O1v1	×	DSMZ Culture Collection	Toothbrush holder
<i>Klebsiella oxytoca</i>	170748	O1v1	×	Clinical Isolate	Catheter specimen urine
	5175	KL29	×	DSMZ Culture Collection	Pharyngeal tonsil
<i>Klebsiella pneumoniae</i>	25736	KL74	✓	DSMZ Culture Collection	Case of pneumonia
	170821	OL104	✓	Clinical Isolate	Urine
	171266	OL104	×	Clinical Isolate	Urostomy urine
	170958	KL28	✓	Clinical Isolate	Urine
	171304	KL144	×	Clinical Isolate	Catheter specimen urine
	13440	KL38	✓	NCTC Culture Collection	Clinical
	13442	KL110	×	NCTC Culture Collection	Hospital, Italy
	30104	KL3	✓	DSMZ Culture Collection	Human blood
	13465	KL57	×	NCTC Culture Collection	Clinical
	170820	KL158	×	Clinical Isolate	Urine
<i>Klebsiella variicola</i>	16358	KL4	×	DSMZ Culture Collection	Human, nose
	170723	KL2	✓	Clinical Isolate	Urine
	171167	KL2	×	Clinical Isolate	Urine
	13443	KL2	×	NCTC Culture Collection	Clinical
	13882	KL64	×	ATCC Culture Collection	Water
	13439	KL14	✓	NCTC Culture Collection	Outbreak strain
	W12	KL14	×	Environmental Isolate	Soil
	15968	KL16	✓	DSMZ Culture Collection	Banana root
<i>Klebsiella quasipneumoniae</i>	28211	KL35	✓	DSMZ Culture Collection	Human blood
	700603	KL53	✓	ATCC Culture Collection	Urine

Capsule and LPS antigen locus types are given where applicable, alongside the origin of the strain and indication of use as an isolation host. LPS, lipopolysaccharide.

TABLE 2. PHAGE ISOLATE DETAILS

Phage name	Lab ID	Life style lytic (L) or temperate (T)	Source of isolation	Strain of isolation	Capsule (K) and LPS antigen (O) locus	Accession no.
Klebsiella phage vB_KppS-Eggy	49	T	Sewage—anoxic sludge	Spernal sewage works, United Kingdom	<i>Klebsiella pneumoniae</i> DSM 30104	KL3 PRJEB40146
Klebsiella phage vB_KppS- Pokey	50	T	Sewage—anoxic sludge	Spernal sewage works, United Kingdom	<i>K. pneumoniae</i> DSM 30104	KL3 PRJEB40147
Klebsiella phage vB_KppS-Raw	33	T	Sewage—raw	Spernal sewage works, United Kingdom	<i>K. pneumoniae</i> DSM 30104	KL3 PRJEB40132
Klebsiella phage vB_KppS-Ant	35	T	Sewage—anoxic sludge	Spernal sewage works, United Kingdom	<i>K. pneumoniae</i> DSM 30104	KL3 PRJEB40148
Klebsiella phage vB_KaS- Ahsoka	7	L	Slurry	Slurry tank, United Kingdom	<i>Klebsiella aerogenes</i> DSM 30053	— PRJEB40160
Klebsiella phage vB_KaS- Gatomon	6	L	Marine canal	Grand canal, Venice, Italy	<i>K. aerogenes</i> DSM 30053	— PRJEB40159
Klebsiella phage vB_KppS- Samwise	8	L	Slurry	Slurry tank, United Kingdom	<i>K. pneumoniae</i> DSM 30104	KL3 PRJEB40161
Klebsiella phage vB_KvM- Eowyn	4	L	Estuary	Jelitkowo, Poland	<i>Klebsiella variicola</i> DSM 15968	KL16 PRJEB40131
Klebsiella phage vB_KpP- Screen	46	L	Sewage—sieve	Spernal sewage works, United Kingdom	<i>K. pneumoniae</i> 170723	KL2 PRJEB40164
Klebsiella phage vB_KpP-Yoda	43	L	Sewage—storm tank	Spernal sewage works, United Kingdom	<i>K. pneumoniae</i> 170723	KL2 PRJEB40162
Klebsiella phage vB_KqP- Goliath	44	L	Sewage—raw	Spernal sewage works, United Kingdom	<i>Klebsiella quasipneumoniae</i> DSM 700603	KL53 PRJEB40163
Klebsiella phage vB_KaS-Benoit	1	L	Estuary	Jelitkowo, Poland	<i>K. aerogenes</i> DSM 30053	— PRJEB39773
Klebsiella phage vB_KaS- Veronica	2	L	Marine canal	Grand canal, Venice, Italy	<i>K. aerogenes</i> DSM 30053	— PRJEB40165
Klebsiella phage vB_KppS- Anoxic	52	L	Sewage—anoxic sludge	Spernal sewage works, United Kingdom	<i>K. pneumoniae</i> DSM 30104	KL3 PRJEB40170
Klebsiella phage vB_KppS-Jiji	27	L	Pond	Gneiwkowo, Poland	<i>K. pneumoniae</i> DSM 30104	KL3 PRJEB40168
Klebsiella phage vB_KppS- Ponyo	19	L	River	Gneiwkowo, Poland	<i>K. pneumoniae</i> DSM 30104	KL3 PRJEB40167

(continued)

TABLE 2. (CONTINUED)

Phage name	Lab ID	Life style lytic (L) or temperate (T)	Source of isolation	Strain of isolation	Capsule (K) and LPS antigen (O) locus	Accession no.
Klebsiella phage vB_KppS-Storm	34	L	Sewage—storm tank	Spernal sewage works, United Kingdom	KL3	PRJEB40169
Klebsiella phage vB_KppS-Totoro	10	L	Estuary	Jelitkowo, Poland	KL3	PRJEB40166
Klebsiella phage vB_KqM-Bilbo	38	L	Sewage—raw	Spernal sewage works, United Kingdom	KL35	PRJEB40172
Klebsiella phage vB_KqM-LilBean	36	L	Sewage—raw	Spernal sewage works, United Kingdom	KL35	PRJEB40171
Klebsiella phage vB_KqM-Westerburg	39	L	Sewage—raw	Spernal sewage works, United Kingdom	KL35	PRJEB40173
Klebsiella phage vB_KoM-Liquor	61	L	Sewage—mixed liquor	Spernal sewage works, United Kingdom	OL104	PRJEB40174
Klebsiella phage vB_KoM-MeTiny	68	L	Sewage—mixed liquor	Spernal sewage works, United Kingdom	KL74	PRJEB40179
Klebsiella phage vB_KoM-Pickle	12	L	Estuary	Jelitkowo, Poland	KL74	PRJEB40176
Klebsiella phage vB_KpM-KalID	67	L	Sewage—mixed liquor	Spernal sewage works, United Kingdom	KL14	PRJEB40178
Klebsiella phage vB_KpM-Mild	65	L	Sewage—mixed liquor	Spernal sewage works, United Kingdom	KL14	PRJEB40177
Klebsiella phage vB_KoM-Milk	62	L	Sewage—mixed liquor	Spernal sewage works, United Kingdom	OL104	PRJEB40175
Klebsiella phage vB_KpM-SoFaint	70	L	Sewage—mixed liquor	Spernal sewage works, United Kingdom	KL38	PRJEB40180
Klebsiella phage vB_KoM-Flushed	63	L	Sewage—mixed liquor	Spernal sewage works, United Kingdom	KL28	PRJEB40181
Klebsiella phage vB_KpM-Wobble	64	L	Sewage—mixed liquor	Spernal sewage works, United Kingdom	KL28	PRJEB40182

Lab ID refers to the laboratory identification number, source of isolation indicates where the water sample was collected for phage enrichment and isolation, and the strain of isolation indicates *Klebsiella* sp. strain on which three rounds of plaque assay isolation were performed. Accession numbers refer to the associated project accession numbers assigned by the ENA for each phage.

a protein column with a 30 kDa cutoff. Seven hundred fifty microliters of concentrated phage was treated with DNase I and Proteinase K, before phenol–chloroform, then overnight precipitation with ammonium acetate and ethanol at -20°C . The DNA was resuspended in $50\ \mu\text{L}$ of molecular-grade water. For phage DNA with high protein contamination from the method described earlier, the Norgen Phage DNA Isolation Kit was used following the manufacturer's instructions. To assess the quantity and quality of DNA for sequencing, both a spectrophotometer-based method and Qubit were used.

Genome sequencing

Sequencing was performed by MicrobesNG (Birmingham, United Kingdom); briefly, genomic DNA libraries were prepared by using Nextera XT Library Prep Kit (Illumina, San Diego) following the manufacturer's protocol with modifications: 2 ng of DNA were used as the input, and a polymerase chain reaction (PCR) elongation time of 1 min. DNA quantification and library preparations were carried out on a Hamilton Microlab STAR automated liquid handling system. Pooled libraries were quantified by using the Kapa Biosystems Library Quantification Kit for Illumina, on a Roche light cycler 96 quantitative PCR machine. Libraries were sequenced on the Illumina HiSeq by using a 250 bp paired end protocol.

Bioinformatics

Contig and genome assembly was carried out by MicrobesNG; reads were trimmed with Trimmomatic 0.30, sliding window quality cutoff of Q15²⁸; and SPAdes (v3.7) was used for *de novo* assembly.²⁹ Genomes were annotated by using Prokka,³⁰ with a custom database downloaded from Genbank as previously described.³¹ The capsule types of the *Klebsiella* strain genomes were predicted by using Kaptive.³²

To determine phage taxonomy, phage isolate genomes were added to VIPtree³³ and subject to BLASTn and tBLASTn against NCBI. The average nucleotide identity (ANI) of our phages was compared with the genomes identified from the methods described earlier by using orthoANI.³⁴ Genomes with an ANI >95% were designated as the same species.³⁵

For genus-level clustering, a shared protein network analysis was performed by using vConTACT2 (v0.9.13)³⁶ with all phage genomes available (May 2020).³¹ The resulting network graph was visualized and annotated within Cytoscape (v3.8.0).³⁷ Finally, sequence alignments were performed by using MAFFT (v7.271)³⁸ on the DNA polymerase, large terminase subunit, and major capsid proteins of each phage isolate genus with the most closely related phage proteins. Phylogenetic trees were constructed with RaxML (v8.2.4)³⁹ with 1000 bootstrap calculations by using the GAMMA model of heterogeneity and the maximum-likelihood method based on the JTT substitution matrix. Subsequent trees were visualized and annotated in R (v3.6.1) by using ggtree (v1.16.6)^{40,41} and phytools (v0.7-70).⁴²

Depolymerases were predicted in the phage isolate's structural genes, through enzymatic domains or features common to characterized depolymerase proteins. Each prediction was analyzed by BLASTP (v2.10.0), Pfam HMMER (v3.3), and HHpred (v33.1) by using the default settings. Sequences from biochemically characterized depolymerase proteins that target *Klebsiella* spp. (Supplementary Table S1)

or the putative depolymerases from our phage isolates (Supplementary Table S2) were used for analysis. Sequences were aligned with Muscle (v3.8.31)⁴³ by using SeaView (v4).⁴⁴

Phylogenetic tree construction was performed with MegaX⁴⁵ with 500 bootstrap calculations by using the LG model. Tree topology searches were performed by using a combination of NNI and NJ/BioNJ. The tree was subsequently visualized and annotated by using iTOL (v4).⁴⁶

Host range testing

Spot testing was carried out; $5\ \mu\text{L}$ of phage stock serial dilutions was plated on to bacterial lawn, in 0.4% overlay agar. Zones of bacterial lawn clearing, indicating cell lysis, were recorded as follows: (1) visible plaques, (2) complete bacterial lawn clearing, (3) turbid bacterial lawn, or (4) no effect. The presence or absence of halos; reduced turbidity of the bacterial lawn surrounding the plaques or clearing were also recorded.

Plaque formation and morphology

Phages were plated by using the overlay agar plaque assay method, as described earlier, on their isolation host. Plates were incubated overnight at 37°C to allow plaques to form. Plaque morphology was noted (halos/no halo), and photographs were taken.

Transmission electron microscopy

Pure phage stocks were imaged by transmission electron microscopy (TEM) on glow-discharged (1 min under vacuum) formvar/carbon-coated copper grids (Agar Scientific Ltd, United Kingdom). Five microliters of phage stock was applied to a grid and incubated for 1.5 min at room temperature. The grid was blotted to remove excess liquid. A drop of 2% uranyl acetate stain was applied and incubated for 1 min, before blotting off; staining was repeated four times; and finally the grid was air dried. Stained phage grids were imaged on a JEOL 2100Plus TEM. The morphology of the phage particles was visualized in ImageJ; 30 capsids and tails for each phage isolate were measured by using the measure function.

Lysis period

Klebsiella cultures in the exponential growth phase were adjusted to $\text{OD}_{600\text{nm}}$ of 0.2, using a spectrophotometer and phage lysates were diluted 1:4. The $\text{OD}_{600\text{nm}}$ was measured every 5 min for 16 h. Growth was compared with a positive control culture without the addition of phages. The lysis period was calculated by measuring the time from phage addition to a drop in culture $\text{OD}_{600\text{nm}}$, relative to the positive control, indicating bacterial cell lysis.

Virulence

Two metrics the virulence index (VP) and MV50 were calculated based on the protocol described by Storms et al.⁴⁷ Briefly, bacterial cultures were grown to the exponential phase and adjusted (see Lysis Period section) to an optical density equivalent to 1×10^8 cfu/mL.

In a 96-well plate, phages were serially diluted from 1×10^8 to 10 pfu/mL in $100\ \mu\text{L}$ volumes. A bacterial culture was then added in equal volume ($100\ \mu\text{L}$) to the phage

dilution, resulting in multiplicity of infections (MOIs) from 1 to 10^{-7} . The optical density of the 96-well plate was read at 600 nm at 5 min intervals for 18 h.

The area under the curve was calculated for the bacterial-only control and at each phage MOI, from initial infection until the exponential growth stage. The VP at each MOI was calculated from this by following the method described⁴⁷ using RStudio (version 1.1.463). VP is a quantified measure of the virulence of a phage against a bacterial host on a scale of 0–1 (0=no reduction in bacterial growth to 1, instantaneous complete killing); the MV50 calculates the theoretical MOI at which a phage achieves a VP of 0.5 (half the theoretical maximum virulence).

Data visualization

Resulting graphs were visualized in R (v3.6.1) implemented through RStudio (v1.1.456)⁴⁸ by using the ggplot2 (v3.3.2) package,⁴⁹ with a custom color-blind palette generated from ColorBrewer.

Results

Klebsiella capsule and LPS antigen locus types

Kaptive determined that the 24 *Klebsiella* strains belonged to 18 different capsule (K) and LPS antigen (O) locus types (Table 1). Three *K. pneumoniae* strains were identified as capsule type KL2; two *Klebsiella* sp. were each typed as O1v1, OL104, and KL14. All other types were unique. *K. aerogenes* 30053 could not be typed.

Sequence similarity to known phages

The 30 *Klebsiella* phages were purified by multiple rounds of plating, and genome sequencing showed a genome size range from 16,548 to 268,500 bp. The *Klebsiella* phage genomes represented nine diverse, distinct genera, as determined by VIPtree (Fig. 1) and vConTACT2 (Fig. 2). Genome similarities between our phage isolates and known phages are given in Table 3.

Phage isolates were grouped at genus-level into groups A–I, referred to, respectively, by their genera or closest identifiable taxonomy level: *Nonagvirus*, unclassified family/genus, *Tempevirinae* unclassified, *Myoviridae* unclassified, *Drulivirus*, *Sugarlandvirus*, *Taipeivirus*, *Slopekivirus*, and *Jiaodavirus*. The phage isolates of groups B–D displayed lower sequence similarities to previously identified phages, hence they were not classified into known genera. The sequence data were deposited in the ENA; accession numbers are given in Table 2.

Alignments constructed in VIPtree³³ showed that the phage groups with the highest levels of amino acid identity and gene synteny to known phages were F, G, H, and I (*Drulivirus*, *Sugarlandvirus*, *Taipeivirus*, and *Jiaodavirus* genera, respectively; Supplementary Figs. S6–S9). Phage isolates in group F, *Sugarlandvirus*, showed the greatest similarity to previously described phages (Supplementary Fig. S6). All *Sugarlandvirus* isolates were grouped with previously described vB_Kpn_IME260 and *Klebsiella* phage Sugarland, except vB_KaS-Veronica, which represents a new species based on ANI. The *Sugarlandvirus* isolates did exhibit variation in their tail fiber genes (Supplementary

Fig. S7; at ~75 kb). In contrast, phage isolates in group A (*Nonagvirus*) were more similar to each other than previously known phages (Supplementary Fig. S2).

There was low sequence identity between our isolates and previously sequenced phages for groups B–D (Supplementary Figs. S3–S5); as a result, the isolates in these groups have unresolved taxonomies. Interestingly, analysis of the phage with the smallest genome, vB_KppS-Ant of group B, revealed >99% nucleotide identity to region of the *K. pneumoniae* 30104 genome (data not shown).

For further similarity analysis between our isolates and known phages, protein phylogenetic trees were drawn for marker genes (DNA polymerase, major capsid protein and terminase large subunit; Supplementary Figs. S10–S18). Conserved branching patterns, indicating close evolutionary history, were observed for groups A and E–I, confirming that they belong to known genera (Supplementary Figs. S10 and S14–S18), whereas groups B–D (Supplementary Figs. S11–S13) do not.

Given more distant relationships between the marker protein sequences, it is proposed that group C represents a novel genus of the subfamily *Tempevirinae* (Supplementary Fig. S12) and group D represents a novel genus of the *Myoviridae* family (Supplementary Fig. S13), whereas the marker genes of the phage isolate of group B has an even more distant relationship with phages of both *Siphoviridae* and *Myoviridae* families (Supplementary Fig. S11). Given the inovirus morphology observed for group B (Fig. 5, black box), classification at the family level also remains unresolved.

Host range testing

Most phages had a host range that extended past their isolation host and was not explained by depolymerase activity. The number of strains infected by each phage is displayed in Figure 3.

The infection range of the two putatively temperate phage genera was limited to their isolation host; *Nonagvirus* (except vB_KppS-Raw, which infected one additional strain) and unclassified family/genera (B).

The lytic phage genera *Myoviridae* unclassified, *Drulivirus* and *Taipeivirus* cleared a bacterial lawn in three to seven *Klebsiella* strains and formed plaques in one to seven of those strains. *Sugarlandvirus* phages showed a clearance of 16 and produced plaques in 10 *Klebsiella* strains; *Tempevirinae* phages were highly variable, with vB_KaS-Gatomon and vB_KaS-Ahsoka forming plaques on only their isolation host; and vB_Kpp-Samwise formed plaques in seven strains and cleared a further five strains.

The broadest range were lytic phages belonging to the subfamily *Tevenvirinae*; *Slopekivirus* and *Jiaodavirus*, which demonstrated clearance in 23 and 17 strains, respectively, and produced plaques on 13 and 9 strains, respectively. Within these genera, the host range varied between individual phages; from *Slopekivirus*, phage vB_KoM-Pickle only formed plaques on its isolation host, yet showed lawn clearance in 22 out of 23 *Klebsiella* spp. (Fig. 3).

Phage annotation

Genome annotation is notoriously difficult with phages, given the extremes of sequence variation evident in all phage proteins,^{50,51} PROKKA was used and identified key phage




FIG. 1. Protein-level phylogenetic tree, generated by VIPTree. *Klebsiella* phage isolates (★). A–I denote phage groups with the following genera: A (red) *Nonagvirus*; B (black) unclassified family/genus; C (blue) *Tempevirinae* unclassified; D (lime) *Myoviridae* unclassified; E (green) *Drulisvirus*; F (purple) *Sugarlandvirus*; G (orange) *Taipeivirus*; H (brown) *Slopekvirus*; and I (pink) *Jiaodavirus*. Icons indicate phage morphology.

genes, for example, portal proteins, capsid genes, tail proteins, and components of the DNA replication. In addition, PhoH was a common feature in 18 out of 30 phages sequenced, including phages from *Myoviridae* unclassified, *Sugarlandvirus*, *Taipeivirus*, and *Slopekvirus*, respectively. Holin and lysin pairs were identified in groups *Nonagvirus*, *Tempevirinae* unclassified, and *Taipeivirus*, whereas endolysin and Rz1 spanin complex genes were identified in *Drulisvirus* and *Jiaodavirus*.

Most of our isolated phages encode at least one gene annotated as a putative “tail-fibre” or “tail-spike” protein (Supplementary Table S2). Structural predictions suggested that these proteins adopt beta-helical structures, a common protein architecture of tail-spike proteins and capsule depolymerase enzymes, which are suggested to have evolved from these purely structural proteins,^{52–54} These proteins

also contained predicted enzymatic domains, for example, Pectate_lyase_3 domain or Peptidase_S74 domain, which have been identified in other phage-encoded depolymerases.^{55–58} Several of the phage groups: B, C, F, H, and I, did not contain a predicted tail-fiber depolymerase protein.

For phages encoding a candidate depolymerase, protein sequence relationships were mapped on a tree (Fig. 4). Phages of the genera *Nonagvirus*, and *Drulisvirus* encode a similar predicted depolymerase protein. The putative depolymerases from *Drulisvirus* phages share high sequence conservation (~95% identity, 100% query) to the experimentally characterized depolymerase Kpv74_56 from the closely related *Drulisvirus*, *K. pneumoniae* phage KpV74,⁵⁹ and all these characterized phages infect K2 capsule-producing strains of *Klebsiella*; however, the *Nonagvirus* isolates in our study do not (Fig. 4).




FIG. 2. Network analysis of phage-encoded proteins calculated with vConTACT2. Colored, numbered nodes represent our *Klebsiella* phage isolates, colored according to the phage group and subsequent genera to which each phage belongs. Numbers within nodes indicate the lab identification numbers (Table 2). Our *Klebsiella* phage isolates are colored according to the genera to which the phage belongs: red, *Nonagvirus*; gray, unclassified; blue, *Tempevirinae* unclassified; lime, *Myoviridae* unclassified; green, *Drulisvirus*; purple, *Sugarlandvirus*; orange, *Taipeivirus*; brown, *Slopekvirus*; and Pink, *Jiaodavirus*. The numbers are the lab identification numbers (Table 2). Smaller, black nodes represent previously sequenced phages as references. Edges between nodes represent shared proteins, such that many connecting edges imply greater pairwise shared protein content. Phage nodes are clustered based on shared proteins, with a spring-embedded (force directed) layout visualization created in Cytoscape.

Interestingly, the phages of two further genera; *Myoviridae* unclassified (vB_KqM-Eowyn) and *Taipeivirus* (vB_KqvM-LilBean, vB_KqvM-Bilbo and vB_KqvM-Westerburg) contain multiple putative depolymerase proteins (7, 4, 4, 5, respectively; Fig. 4). The putative depolymerase-like proteins of vB_KqM-Eowyn (*Myoviridae* unclassified) show low identity to previously characterized depolymerases (Fig. 4). From our host range assays, these phages showed activity toward strains that produced a small subset of K-antigens (vB_KqM-Eowyn—KL16, KL110; vB_KqvM-LilBean—KL35; vB_KqvM-Bilbo—KL35, K2 and vB_KqvM-Westerburg—KL35, KL2, KL3).

Morphology of phages

Phage-induced plaques in the lawns of host bacteria varied in size, and in the presence/absence of halos surrounding the phage plaques. Representative images of phage plaques for each described genera are presented in Figure 5. A diffuse halo around the phage plaques was observed in 15 of the 30 phage isolates (Supplementary Table S3 and Fig. 5).

Representative TEM images of the described phage genera are provided in Figure 5. Average tail length and capsid widths are given in Supplementary Table S3 (based on 30 particles per phage), and a representative TEM image for each phage is given in Figure 5. Of the phages imaged, 13 are myovirus, 13 are siphovirus, 3 are podovirus, and 1 is inovirus.

The largest phage in this study was vB_KvM-Eowyn (*Myoviridae* unclassified), which had a capsid width of 140 nm and a tail length of 140 nm; this corresponded to the largest genome at 269 kbp. The smallest caudovirale phage was vB_KqP-Goliath, a podovirus (*Drulisvirus*), with a capsid

width of 41 nm and tail length of 10 nm, had the second smallest genome at 44 kbp, after the filamentous prophage vB_KppS-Ant (unclassified family/genus). vB_KppS-Raw (*Nonagvirus*), a siphovirus, had a comparable capsid size of 46 nm, but a substantially longer tail (153 nm) and genome of 61 kbp. The smallest caudovirale phages (*Drulisvirus*) produced the largest plaques and halos, hence the name KqP-Goliath (Supplementary Table S1 and Fig. 5).

Phage lysis period and virulence in host strains

The lysis period and virulence indices (VP and MV50) of each phage, in their relevant isolation host strain in LB at 37°C, are displayed in Figure 6. For six phages a lysis period was not achieved (vB_KppS-Eggy, vB_KppS-Pokey, vB_KppS-Ant, vB_KpM-Milk, vB_KpM-KalD, and vB_KpM-SoFaint), and the growth curve of the bacteria was dampened (except vB_KppS-Ant); however, the culture density did not crash compared with the positive control—indicative of temperate phages. These phages also demonstrated a below-average VP, close to 0 (with the exception of vB_KpM-KalD), indicating little difference in growth curves between the control and phage-infected cultures (Fig. 6).

Of the phages with a lysis period, the median time was ~70 min, ranging from 15 to 210 min. There was no correlation between lysis period and the virulence measures (Fig. 6; statistical data not shown). The average VP was 0.33 (range 0.06–0.64) and MV50 was achieved with a projected MOI of 4.17×10^{17} (range 3.5×10^{-7} to 1×10^{19}) for the lytic phage genera. The putatively temperate phages had lower virulence measures; average VP 0.06 (range –0.07 to 0.36) and MV50 returned a theoretical MOI of 6.00×10^{58} (range 0.012 to 3×10^{59}).

TABLE 3. PHAGE TAXONOMY AND SIMILARITY TO CLOSEST SEQUENCED PHAGE

Phage name	Phage group	Taxonomy			Comparison phage		
		Family	Subfamily	Genus	Phage name	Accession	ANI
vB_Kpps-Eggy	A	Siphoviridae		<i>Nonagvirus</i>	Enterobacteria phage JenP2	KP719132	65.86
vB_Kpps-Pokey	A	Siphoviridae		<i>Nonagvirus</i>	Enterobacteria phage JenP2	KP719132	66.69
vB_Kpps-Raw	A	Siphoviridae		<i>Nonagvirus</i>	Enterobacteria phage JenP2	KP719132	66.77
vB_Kpps-Ant	B	Siphoviridae		unclassified	Caudovirales_phage_clone_3F_1	MF417951	90.14
vB_KaS-Ahsoka	C	Drexlerviridae	Tunavirinae	unclassified	Escherichia phage Henu7	MN019128	92.09
vB_KaS-Gatomon	C	Drexlerviridae	Tunavirinae	unclassified	Escherichia phage Henu7	MN019128	93.55
vB_Kpps-Samwise	C	Drexlerviridae	Tunavirinae	unclassified	Escherichia phage Henu7	MN019128	93.55
vB_KvM-Eowyn	D	Myoviridae	Tempevirinae	unclassified	Serratia_phage_KpHz_2	KF806589	95.02
vB_KpP-Screen	E	Autographiviridae	Slopekvirinae	<i>Druisivirus</i>	Klebsiella phage vB_KpnP_SU552A	KP708986	86.58
vB_KpP-Yoda	E	Autographiviridae	Slopekvirinae	<i>Druisivirus</i>	Klebsiella phage vB_KpnP_SU552A	KP708986	87.03
vB_KqP-Goliath	E	Autographiviridae	Slopekvirinae	<i>Druisivirus</i>	Klebsiella phage vB_KpnP_SU552A	KP708986	85.82
vB_KaS-Benoit	F	Demereciviridae		<i>Sugarlandvirus</i>	vB_Kpn_IME260	NC_041899	94.29
vB_KaS-Veronica	F	Demereciviridae		<i>Sugarlandvirus</i>	★Klebsiella phage Sugarland	NC_042093	93.46
vB_Kpps-Anoxic	F	Demereciviridae		<i>Sugarlandvirus</i>	vB_Kpn_IME260	NC_041899	96.11
vB_Kpps-Jiji	F	Demereciviridae		<i>Sugarlandvirus</i>	★Klebsiella phage Sugarland	NC_042093	93.26
vB_Kpps-Ponyo	F	Demereciviridae		<i>Sugarlandvirus</i>	★Klebsiella phage Sugarland	NC_042093	94.15
vB_Kpps-Storm	F	Demereciviridae		<i>Sugarlandvirus</i>	★Klebsiella phage Sugarland	NC_042093	95.02
vB_Kpps-Totoro	F	Demereciviridae		<i>Sugarlandvirus</i>	vB_Kpn_IME260	NC_041899	94.29
vB_KqM-Bilbo	G	Ackermannviridae		<i>Taipeivirus</i>	★Klebsiella virus 0507KN21	NC_022343	97.22
vB_KqM-LiBean	G	Ackermannviridae		<i>Taipeivirus</i>	★Klebsiella virus 0507KN21	NC_022343	97.83
vB_KqM-Westerburg	G	Ackermannviridae		<i>Taipeivirus</i>	★Klebsiella virus 0507KN21	NC_022343	96.93
vB_KoM-Liquor	H	Myoviridae	Tevenvirinae	<i>Slopekivirus</i>	★Klebsiella phage KP15	GU295964	97.83
vB_KoM-MeTiny	H	Myoviridae	Tevenvirinae	<i>Slopekivirus</i>	★Klebsiella phage KP15	GU295964	97.92
vB_KoM-Pickle	H	Myoviridae	Tevenvirinae	<i>Slopekivirus</i>	★Klebsiella phage KP15	GU295964	97.93
vB_KpM-KalD	H	Myoviridae	Tevenvirinae	<i>Slopekivirus</i>	★Klebsiella phage KP15	GU295964	97.42
vB_KpM-Mild	H	Myoviridae	Tevenvirinae	<i>Slopekivirus</i>	★Klebsiella phage KP15	GU295964	97.65
vB_KpM-Milk	H	Myoviridae	Tevenvirinae	<i>Slopekivirus</i>	★Klebsiella phage KP15	GU295964	98.38
vB_KpM-SoFaint	H	Myoviridae	Tevenvirinae	<i>Slopekivirus</i>	★Klebsiella phage KP15	GU295964	97.72
vB_KoM-Flushed	I	Myoviridae	Tevenvirinae	<i>Jiaodavirus</i>	★Klebsiella phage JD18	KT239446	96.19
vB_KpM-Wobble	I	Myoviridae	Tevenvirinae	<i>Jiaodavirus</i>	★Klebsiella phage JD18	KT239446	97.01

Family, Subfamily, and Genus are assigned based on the clustering patterns observed in vConTACT2 analysis (Fig. 2), and conserved branching patterns observed in the marker gene phylogenetic trees (Supplementary Figs. S10–S18). ANI calculated with orthoANI. Details for “comparison phage” relate to details of previously sequenced phages available in public databases used for ANI analysis, ★ in front on the comparison phage name indicates it is the type species.




FIG. 5. Phage morphology, TEM, and plaque morphology. Colored boxes are drawn according to the phage group and subsequent genera to which each phage belongs: A (*Nonagvirus*; B (black) unclassified family/genus; C (blue) *Tempevirinae* unclassified; D (lime) *Myoviridae* unclassified; E (green) *Slopevirus*; F (purple) *Sugarlandvirus*; G (orange) *Taipeivirus*; H (brown) *Slopevirus*; and I (pink) *Jiaodavirus*. The clearest TEM images were selected for each phage, scales vary for each image, and nm scale bars are included for each image. An image of the plaques produced by each phage is included after overnight incubation at 37°C on agar overlay plates. TEM, transmission electron microscopy.




FIG. 6. Lysis period and virulence indices are not correlated, but temperate phages are less virulent. **(A)** Displays the virulence index of the phages. Virulence index is a quantified measure of the phage, in their respective isolation host (Table 2), in LB with 5 mM each of CaCl_2 and MgCl_2 , at 37°C . **(B)** displays the MV50, the MOI at which each phage achieves 50% of their maximal theoretical virulence. Both of these virulence measures are described in more detail by Storms.⁴⁷ **(C)** Displays the lysis period of the phage. Where this is left blank, a lysis period could not be established, usually indicating temperate lifestyle. Individual points are colored based on phage group and the subsequent genera to which each phage belongs: A (red) *Nonagvirus*; C (blue) *Tempevirinae* unclassified; D (lime) *Myoviridae* unclassified; E (green) *Drulisvirus*; F (purple) *Sugarlandvirus*; G (orange) *Taipeivirus*; H (brown) *Slopekavirus*; and I (pink) *Jiaodavirus*. Dashed lines indicate the median values for each metric. MOI, multiplicity of infection.

S11), resulting in divergent characteristics in terms of host range and virulence (Figs. 3 and 6). Despite several of these phage species having been identified in previous studies, there are examples where these showed differences in host range. Thus, even within the small sample presented here, there is information to be gained about the factors determining host range.

It has been suggested that selection pressure imposed from the use of a host is sufficient to amplify nongenetic variants of a phage that can cross host -range,^{47,61} and it also remains possible that uncharacterized genes, encoding proteins of

unknown function, could adapt a given phage to a distinct host.⁶² By way of example, *Sugarlandvirus* phages showed a high degree of similarity between genome sequences, with most variation concentrated in their tail fiber genes. Tail fibers mediate interaction with host cell receptors and are frequently rearranged in phages, allowing them to adhere to bacterial hosts.⁶³ These tail fibers can include domains with enzymatic function, enabling degradation of host-specific features such as polysaccharide capsules.⁶⁴

Three phages with >99% genome sequence similarity were isolated on two distinct hosts: *K. pneumoniae* 30104 (vB_

KppS_Ponyo and vB_KppS_Totoro) or *K. aerogenes* 30053 (vB_KaS-Benoit). vB_KppS_Ponyo and vB_KaS-Benoit are 100% identical at the nucleotide level, and vB_KppS_Totoro has a single nucleotide polymorphism (SNP).

Host range analysis showed that the two phages propagated on *K. pneumoniae* 30104 had comparable host ranges, whereas the phage propagated on *K. aerogenes* 30053 had a slightly different host range (Fig. 3). This indicates that the propagation host, influenced host range, and that genome sequence alone cannot be used to infer host range.⁶⁵ This is a vitally important consideration for phage therapy, and we cannot generalize phage behavior based on genome similarity, but we must also consider prevailing culture conditions.⁶⁶

Although multiple features of strain-specific bacterial immunity can protect against phage replication, in *Klebsiella* the primary defense against both phages and antibiotics is a protective polysaccharide capsule.^{67,68} This capsule forms the outermost layer of the *Klebsiella* cell and acts as an important virulence factor.⁶⁹ There are at least 77 different serologically defined *Klebsiella* capsule types.^{70,71} Whole-genome capsule typing³² showed that our *Klebsiella* panel encompassed 18 capsule types, including three KL2 strains, which are important in clinical infections and therefore of interest to develop effective therapies.⁹

Klebsiella phages have repeatedly shown to be specific to host capsule types,⁷²⁻⁷⁴ and this is often linked to phage sugar-degrading enzymes called depolymerases that target specific capsule types.^{56,59,75} Given the broad host ranges observed in our collection of phages (Fig. 3) and depolymerase-indicative halos⁷⁶ in 83% of our phage isolates (Supplementary Table S3), we sought to identify depolymerase genes.

A surprisingly high number of putative depolymerase genes (7) were identified in vB_KvM-Eowyn (*Myoviridae* unclassified), which only produced plaques in its KL16 host strain, but showed potential depolymerase activity against a KL110-producing strain.

The *Taipeivirus* phages encoded four to six depolymerases, each of which also exceeded the number expected⁵³; these phages produced plaques against the clinically relevant KL2 capsule type. These depolymerases have yet to be verified, and a wider panel of *Klebsiella* capsule types is necessary to confirm their activity. *Klebsiella* phages encoding up to 11 depolymerase genes have previously been characterized, but these infect a correspondingly wide range of *Klebsiella* capsule types,⁷⁷ indicating a need to expand our *Klebsiella* panel.

Nonagvirus and *Drulisvirus* phages encoded one depolymerase gene each and demonstrated a small host range (Fig. 3). Characterization of these putative depolymerase genes will be important to further investigate the potential host range of these phages, beyond our current analysis. Genes encoding depolymerases were not identifiable in all of our halo-producing phages, including in some of the broadest ranging phages: *Sugarlandvirus*, *Slopekvirus*, and *Jiaodavirus*. The phage with the broadest host range, KoM-MeTiny (*Slopekvirus*), showed lawn clearance in 79% and produced plaques in 42% of the *Klebsiella* tested, which included nine different capsule types, but had no identifiable depolymerase genes. We suggest that this is either because they lack depolymerases or due to inadequate tools for depolymerase identification.^{50,51}

There is limited sequence conservation between many of the putative tail-fiber/tail-spike depolymerase proteins from

our phages and biochemically validated depolymerases, therefore further characterization will be critical to optimize phage cocktails for therapeutic use.

Application to future phage-based therapy

None of our lytic phages was able to suppress *Klebsiella* growth for more than 12 h (Supplementary Fig. S1). In addition, selecting effective phages for the bacteria to be targeted can improve phage performance; phage vB_KoM_Liquor had an exceptionally long lysis period of 210 min, possibly due to poor propagation in the isolation host *K. oxytoca* 170821. Phage cocktails are used to improve the impact of phages on *Klebsiella* populations and are considered crucial for the efficacy of phage therapy.⁷⁸⁻⁸⁰ Phage cocktails benefit from complementarity and redundancy between the phages to overcome host-evolved phage resistance,⁸¹ which may account for the resurgences seen in our *Klebsiella* cultures.

After phage selection, the testing of phage combinations is essential to avoid adverse effects, which could result in bacterial stress responses or biofilm formation, as seen with sub-lethal antibiotic use.^{82,83} The phages described in this study have been supplied for use in compassionate phage therapy cocktails, requiring rigorous and lengthy testing to ensure safety and activity against the clinical *Klebsiella*.

For use in phage therapy, phages must not encode toxins or AMR genes.^{78,80,84} Fortunately, none of our *Klebsiella* phages contained either. Other factors, for example, the host infection dynamics and low virulence of the *Nonagvirus* indicate that these isolates may be temperate and/or may not be curative on infections. The temperate phage vB_KppS-Ant, as the only phage with an identifiable integrase for lysogeny, will be excluded for phage therapy purposes.⁸⁵ *Jiaodavirus* phages encode a Hoc-like protein, which in phage T4 has been demonstrated to be highly immunogenic.⁸⁶ It should be established as to whether these phages cause an immune response before using them for phage therapy.

The genomic information and experimental data presented here for *Tempevirinae* unclassified, *Sugarlandvirus*, *Taipeivirus*, and *Slopekvirus* indicate that they are lytic and, thus, suitable for preclinical evaluation. We suggest that the *Sugarlandvirus* and *Slopekvirus* isolates are the best candidates for future development in phage therapy, given their broad host range, high virulence, short latency period, and lack of potentially harmful genes. Taken together, our data suggest that to provide universal, effective phage therapy against *Klebsiella* infections, a phage cocktail comprising multiple diverse phages should be developed.

Conclusions

A diverse range of *Klebsiella* phages were isolated. Despite some of our phage isolates being grouped into a single previously described phage species, within-species variation in both host range and virulence was observed. This demonstrates the necessity to microbiologically characterize phages for therapeutic use.

Authors' Contributions

E.M.T. and E.J. designed the experiments. E.J., E.M.T., L.K., L.G., H.S., S.J.K., A.K., and S.M. performed the experiments. E.J., E.M.T., A.D.M., R.D., T.L., and G.M.

analyzed data. S.J.K., A.K., and M.S. provided working knowledge of phage therapy. E.J., E.M.T., G.M., and R.D. contributed to the writing of this article. All authors have reviewed and approved the article before submission and agree to be accountable for all aspects of the work.

Acknowledgments

The authors acknowledge the help of Severn Trent for enabling them to collect sewage samples from Sperial sewage treatment works. They also acknowledge the Midlands Regional Cryo-EM Facility, hosted at the Warwick Advanced Bioimaging Research Technology Platform, for use of the JEOL 2100Plus, supported by MRC award reference MC_PC_17136. Genome sequencing was provided by MicrobesNG.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

This work was supported by a Warwick Integrative Synthetic Biology (WISB) early career fellowship, funded jointly by BBSRC and EPSRC to E.J. and the Monash Warwick Alliance Accelerator Fund October 2019 to E.J. and T.L. Bioinformatics analysis was carried out by infrastructure provided by MRC CLIMB (MR/T030062/1). The work has also been supported by PhD fellowships awarded to L.K., L.G., G.M., and H.S. through DTPS funded by BBSRC and EPSRC.

Supplementary Material

Supplementary Figure S1
 Supplementary Figure S2
 Supplementary Figure S3
 Supplementary Figure S4
 Supplementary Figure S5
 Supplementary Figure S6
 Supplementary Figure S7
 Supplementary Figure S8
 Supplementary Figure S9
 Supplementary Figure S10
 Supplementary Figure S11
 Supplementary Figure S12
 Supplementary Figure S13
 Supplementary Figure S14
 Supplementary Figure S15
 Supplementary Figure S16
 Supplementary Figure S17
 Supplementary Figure S18
 Supplementary Table S1
 Supplementary Table S2
 Supplementary Table S3

References

- Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev.* 1998;11:589–603.
- Dhesi Z, Enne VI, Brealey D, et al. Organisms causing secondary pneumonias in COVID-19 patients at 5 UK ICUs as detected with the FilmArray test. medRxiv 2020:2020.2006.2022.20131573.
- He Y, Li W, Wang Z, et al. Nosocomial infection among patients with COVID-19: A retrospective data analysis of 918 cases from a single center in Wuhan, China. *Infect Control Hosp Epidemiol.* 2020;41:982–983.
- Zhu X, Ge Y, Wu T, et al. Co-infection with respiratory pathogens among COVID-2019 cases. *Virus Res.* 2020;285:198005.
- Jameson E, Quareshy M, Chen Y. Methodological considerations for the identification of choline and carnitine-degrading bacteria in the gut. *Methods.* 2018;149:42–48.
- Yan Q, Gu Y, Li X, et al. Alterations of the gut microbiome in hypertension. *Front Cell Infect Microbiol.* 2017;7:381.
- Atarashi K, Suda W, Luo C, et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. *Science.* 2017;358:359–365.
- Bengoechea JA, Sa Pessoa J. *Klebsiella pneumoniae* infection biology: Living to counteract host defences. *FEMS Microbiol Rev.* 2019;43:123–144.
- Choby JE, Howard-Anderson J, Weiss DS. Hypervirulent *Klebsiella pneumoniae*—clinical and molecular perspectives. *J Intern Med.* 2020;287:283–300.
- Holt KE, Wertheim H, Zadoks RN, et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in *Klebsiella pneumoniae*, an urgent threat to public health. *Proc Natl Acad Sci U S A.* 2015;112:E3574–81.
- Shankar C, Nabarro LE, Anandan S, et al. Extremely high mortality rates in patients with carbapenem-resistant, hypermucoviscous *Klebsiella pneumoniae* blood stream infections. *J Assoc Physicians India.* 2018;66:13–16.
- Tacconelli E, Carrara E, Savoldi A, et al. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis.* 2018;18(3):318–327.
- Navon-Venezia S, Kondratyeva K, Carattoli A. *Klebsiella pneumoniae*: A major worldwide source and shuttle for antibiotic resistance. *FEMS Microbiol Rev.* 2017;41:252–275.
- Sanchez GV, Master RN, Clark RB, et al. *Klebsiella pneumoniae* antimicrobial drug resistance, United States, 1998–2010. *Emerg Infect Dis.* 2013;19:133–136.
- Elemam A, Rahimian J, Mandell W. Infection with pan-resistant *Klebsiella pneumoniae*: A report of 2 cases and a brief review of the literature. *Clin Infect Dis.* 2009;49:271–274.
- Sonnevend Á, Ghazawi A, Hashmey R, et al. Multihospital occurrence of pan-resistant *Klebsiella pneumoniae* sequence type 147 with an ISEcp1-directed blaOXA-181 insertion in the mgrB gene in the United Arab Emirates. *Antimicrob Agents Chemother.* 2017;61:e00418-17.
- Turner P, Ashley EA, Celhay OJ, et al. ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): A pilot protocol for case based antimicrobial resistance surveillance. *Wellcome Open Res.* 2020;5:13.
- Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant *Klebsiella pneumoniae* bloodstream infections. *Clin Microbiol Infect.* 2012;18:54–60.
- Mollers M, Lutgens SP, Schoffelen AF, et al. Cost of nosocomial outbreak caused by NDM-1-containing *Klebsiella pneumoniae* in the Netherlands, October 2015–January 2016. *Emerg Infect Dis.* 2017;23:1574–1576.

20. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report 2019. Stockholm: ECDC; 2020.
21. Patro LPP, Rathinavelan T. Targeting the sugary armor of *Klebsiella* species. *Front Cell Infect Microbiol.* 2019;9:367.
22. El Haddad L, Harb CP, Gebara MA, et al. A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. *Clin Infect Dis.* 2019;69:167–178.
23. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant *Mycobacterium abscessus*. *Nat Med.* 2019;25:730–733.
24. Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant *Acinetobacter baumannii* infection. *Antimicrob Agents Chemother.* 2017; 61:e00954-17.
25. Brussow H, Canchaya C, Hardt WD. Phages and the evolution of bacterial pathogens: From genomic rearrangements to lysogenic conversion. *Microbiol Mol Biol Rev.* 2004;68:560–602, table of contents.
26. Adriaenssens EM, Sullivan MB, Knezevic P, et al. Taxonomy of prokaryotic viruses: 2018–2019 update from the ICTV Bacterial and Archaeal Viruses Subcommittee. *Arch Virol* 2020;165:1253–1260.
27. Sambrook J, Fritsch EF, Maniatis T. *Molecular Cloning: A Laboratory Manual*. New York: Cold Spring Harbor Laboratory Press; 1989.
28. Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics.* 2014; 30:2114–2120.
29. Bankevich A, Nurk S, Antipov D, et al. SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol.* 2012;19:455–477.
30. Seemann T. Prokka: Rapid prokaryotic genome annotation. *Bioinformatics.* 2014;30:2068–2069.
31. Michniewski S, Redgwell T, Grigonyte A, et al. Riding the wave of genomics to investigate aquatic coliphage diversity and activity. *Environ Microbiol.* 2019;21:2112–2128.
32. Wick RR, Heinz E, Holt KE, et al. Kaptive web: User-friendly capsule and lipopolysaccharide serotype prediction for *Klebsiella* genomes. *J Clin Microbiol.* 2018;56:e00197-18.
33. Rohwer F, Edwards R. The phage proteomic tree: A genome-based taxonomy for phage. *J Bacteriol.* 2002;184: 4529–4535.
34. Lee I, Kim YO, Park S-C, et al. OrthoANI: An improved algorithm and software for calculating average nucleotide identity. *Int J Syst Evol Microbiol.* 2016;66:1100–1103.
35. Adriaenssens E, Brister JR. How to name and classify your phage: An informal guide. *Viruses.* 2017;9:70.
36. Bolduc B, Jang HB, Doulier G, et al. vConTACT: An iVirus tool to classify double-stranded DNA viruses that infect Archaea and Bacteria. *PeerJ.* 2017;5:e3243.
37. Shannon P, Markiel A, Ozier O, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Res.* 2003;13:2498–2504.
38. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. *Mol Biol Evol.* 2013;30:772–780.
39. Stamatakis A. RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics.* 2014;30:1312–1313.
40. Yu G, Smith DK, Zhu H, et al. ggtree: An R package for visualization and annotation of phylogenetic trees with their covariates and other associated data. *Methods Ecol Evol.* 2017;8:28–36.
41. Yu G, Lam TT-Y, Zhu H, et al. Two methods for mapping and visualizing associated data on phylogeny using ggtree. *Mol Biol Evol.* 2018;35:3041–3043.
42. Revell LJ. phytools: An R package for phylogenetic comparative biology (and other things). *Methods Ecol Evol.* 2012;3:217–223.
43. Edgar RC. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* 2004;32:1792–1797.
44. Gouy M, Guindon S, Gascuel O. SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. *Mol Biol Evol.* 2010; 27:221–224.
45. Kumar S, Stecher G, Li M, et al. MEGA X: Molecular evolutionary genetics analysis across computing platforms. *Mol Biol Evol.* 2018;35:1547–1549.
46. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v4: Recent updates and new developments. *Nucleic Acids Res.* 2019;47:W256–W259.
47. Storms ZJ, Teel MR, Mercurio K, et al. The virulence index: A metric for quantitative analysis of phage virulence. *Phage.* 2020;1:27–36.
48. Allaire J. *RStudio: Integrated Development Environment for R*. RStudio, Boston, MA: PBC; 2012. <http://www.rstudio.com/>.
49. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. New York: Springer; 2016.
50. McNair K, Aziz RK, Pusch GD, et al. Phage genome annotation using the RAST pipeline. *Methods Mol Biol.* 2018;1681:231–238.
51. McNair K, Zhou C, Dinsdale EA, et al. PHANOTATE: A novel approach to gene identification in phage genomes. *Bioinformatics.* 2019;35:4537–4542.
52. Squeglia F, Maciejewska B, Łatka A, et al. Structural and functional studies of a *Klebsiella* phage capsule depolymerase tailspike: Mechanistic insights into capsular degradation. *Structure.* 2020;28:613–624.e4.
53. Latka A, Leiman PG, Drulis-Kawa Z, et al. Modelling the architecture of depolymerase-containing receptor binding proteins in *Klebsiella* phages. *Front Microbiol.* 2019;10:2649.
54. Latka A, Maciejewska B, Majkowska-Skrobek G, et al. Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. *Appl Microbiol Biotechnol.* 2017;101:3103–3119.
55. Lin T-L, Hsieh P-F, Huang Y-T, et al. Isolation of a bacteriophage and its depolymerase specific for K1 capsule of *Klebsiella pneumoniae*: Implication in typing and treatment. *J Infect Dis.* 2014;210:1734–1744.
56. Majkowska-Skrobek G, Łatka A, Berisio R, et al. Capsule-targeting depolymerase, derived from *Klebsiella* KP36 phage, as a tool for the development of anti-virulent strategy. *Viruses.* 2016;8:324.
57. Kimura K, Itoh Y. Characterization of poly- γ -glutamate hydrolase encoded by a bacteriophage genome: Possible role in phage infection of *Bacillus subtilis* encapsulated with poly- γ -glutamate. *Appl Environ Microbiol.* 2003;69:2491–2497.
58. Pires DP, Oliveira H, Melo LD, et al. Bacteriophage-encoded depolymerases: Their diversity and biotechnological applications. *Appl Microbiol Biotechnol.* 2016;100:2141–2151.
59. Solovieva EV, Myakinina VP, Kislichkina AA, et al. Comparative genome analysis of novel Podoviruses lytic

- for hypermucoviscous *Klebsiella pneumoniae* of K1, K2, and K57 capsular types. *Virus Res.* 2018;243:10–18.
60. Kleiner M, Hooper LV, Duerkop BA. Evaluation of methods to purify virus-like particles for metagenomic sequencing of intestinal viromes. *BMC Genomics.* 2015;16:7.
 61. Petrie KL, Palmer ND, Johnson DT, et al. Destabilizing mutations encode nongenetic variation that drives evolutionary innovation. *Science.* 2018;359:1542–1545.
 62. Roux S, Enault F, Hurwitz BL, et al. VirSorter: Mining viral signal from microbial genomic data. *PeerJ.* 2015;3:e985.
 63. Sandmeyer H. Acquisition and rearrangement of sequence motifs in the evolution of bacteriophage tail fibres. *Mol Microbiol.* 1994;12:343–350.
 64. Nobrega FL, Vlot M, de Jonge PA, et al. Targeting mechanisms of tailed bacteriophages. *Nat Rev Microbiol.* 2018;16:760–773.
 65. Jensen EC, Schrader HS, Rieland B, et al. Prevalence of broad-host-range lytic bacteriophages of *Sphaerotilus natans*, *Escherichia coli*, and *Pseudomonas aeruginosa*. *Appl Environ Microbiol.* 1998;64:575–580.
 66. Townsend EM, Moat J, Jameson E. CAUTI's next top model—model dependent *Klebsiella* biofilm inhibition by bacteriophages and antimicrobials. *Biofilm.* 2020;2:100038.
 67. March C, Cano V, Moranta D, et al. Role of bacterial surface structures on the interaction of *Klebsiella pneumoniae* with phagocytes. *PLoS One.* 2013;8:e56847.
 68. Whitfield C. Biosynthesis and assembly of capsular polysaccharides in *Escherichia coli*. *Annu Rev Biochem.* 2006;75:39–68.
 69. Simoons-Smit A, Verweij-van Vught A, MacLaren D. The role of K antigens as virulence factors in *Klebsiella*. *J Med Microbiol.* 1986;21:133–137.
 70. Edwards P, Fife MA. Capsule types of *Klebsiella*. *J Infect Dis.* 1952;91:92–104.
 71. Ørskov I. Serological investigations in the *Klebsiella* group. I. New capsule types. *Acta Pathol Microbiol Scand.* 1955;36(5):449–453.
 72. Hsu C-R, Lin T-L, Pan Y-J, et al. Isolation of a bacteriophage specific for a new capsular type of *Klebsiella pneumoniae* and characterization of its polysaccharide depolymerase. *PLoS One.* 2013;8:e70092.
 73. Bhetwal A, Maharjan A, Shakya S, et al. Isolation of potential phages against multidrug-resistant bacterial isolates: promising agents in the rivers of Kathmandu, Nepal. *Biomed Res Int.* 2017;2017:3723254.
 74. Hoyles L, Murphy J, Neve H, et al. *Klebsiella pneumoniae* subsp. *pneumoniae*-bacteriophage combination from the caecal effluent of a healthy woman. *PeerJ.* 2015;3:e1061.
 75. Rieger-Hug D, Stirn S. Comparative study of host capsule depolymerases associated with *Klebsiella* bacteriophages. *Virology.* 1981;113:363–378.
 76. Hughes K, Sutherland I, Clark J, et al. Bacteriophage and associated polysaccharide depolymerases—novel tools for study of bacterial biofilms. *J Appl Microbiol.* 1998;85:583–590.
 77. Pan YJ, Lin TL, Chen CC, et al. *Klebsiella* phage PhiK64-1 encodes multiple depolymerases for multiple host capsular types. *J Virol.* 2017;91:e02457-16.
 78. Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. *Int J Antimicrob Agents.* 2019;53:16–21.
 79. Chan BK, Abedon ST. Phage therapy pharmacology: phage cocktails. *Adv Appl Microbiol.* 2012;78:1–23.
 80. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. *Future Microbiol.* 2013;8:769–783.
 81. Nale JY, Spencer J, Hargreaves KR, et al. Bacteriophage combinations significantly reduce *Clostridium difficile* growth in vitro and proliferation in vivo. *Antimicrob Agents Chemother.* 2016;60:968–981.
 82. Van Laar TA, Chen T, You T, et al. Sublethal concentrations of carbapenems alter cell morphology and genomic expression of *Klebsiella pneumoniae* biofilms. *Antimicrob Agents Chemother.* 2015;59:1707–1717.
 83. Ranieri MR, Whitchurch CB, Burrows LL. Mechanisms of biofilm stimulation by subinhibitory concentrations of antimicrobials. *Curr Opin Microbiol.* 2018;45:164–169.
 84. Ly-Chatain MH. The factors affecting effectiveness of treatment in phages therapy. *Front Microbiol.* 2014;5:51.
 85. Gill JJ, Hyman P. Phage choice, isolation, and preparation for phage therapy. *Curr Pharm Biotechnol.* 2010;11:2–14.
 86. Dąbrowska K, Miernikiewicz P, Piotrowicz A, et al. Immunogenicity studies of proteins forming the T4 phage head surface. *J Virol.* 2014;88:12551.

Address correspondence to:
 Eleanor Jameson, PhD
 M130, School of Life Sciences
 Gibbet Hill Campus
 The University of Warwick
 Coventry CV4 7AL
 United Kingdom

Email: eleanor.jameson@warwick.ac.uk